Q-omics provides the consensus-scored MATR3 profile across patient tissues and cancer cell-line models. MATR3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MATR3 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MATR3 RNA expression shows 21,017 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where MATR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MATR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MATR3 survival associations across molecular data types. MATR3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MATR3 RNA expression–survival associations across cancer types. High MATR3 expression shows unfavorable associations in UVM and CESC, but favorable associations in HNSC, SKCM, READ and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for MATR3 RNA expression.
This table summarizes MATR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MATR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MATR3 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, CHOL and KIRP. The HNSC box plot shows higher MATR3 RNA expression in tumor versus normal tissue (log2 FC = +0.251, t-test p < 0.001).
This table shows molecular features associated with MATR3 in patient tissues and cancer cell lines. In patient samples, MATR3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MATR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
